Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T04:47:39.570Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone and olanzapine in treatment of delusional disorders

Published online by Cambridge University Press:  16 April 2020

N. Zivkovic ,
B. Bajovic ,
G. Djokic ,
D. Pavicevic  and
M. Nenadovic
N. Zivkovic
Affiliation:
Department of Emergency Psichiatry, Belgrade, Serbia
B. Bajovic
Affiliation:
Institute for Neuropsychiatry ‘Dr Laza Lazarevic’, Belgrade, Serbia
G. Djokic
Affiliation:
Institute for Neuropsychiatry ‘Dr Laza Lazarevic’, Belgrade, Serbia
D. Pavicevic
Affiliation:
Institute for Neuropsychiatry ‘Dr Laza Lazarevic’, Belgrade, Serbia
M. Nenadovic
Affiliation:
Institute for Neuropsychiatry ‘Dr Laza Lazarevic’, Belgrade, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Delusional disorders are severe psychotic disorders with characteristic non-bizarre delusions often organized in permanent delusional system.

Aim

To estimate efficacy of risperidone and olanzapine in treatment of DD.

Methods

135 patients with DD were divided into Haloperidol-control (41), Risperidone (49) and Olanzapine group (45 patients). Patients were observed for 6 months according to protocol, which included PANSS Scale and CGI1-4 Scale. Control group was treated with haloperidol 5–30 mg/24 h. Experimental groups were treated with risperidone 2–6 mg/24 h and olanzapine 10–20 mg/24 h.

Results

Pretrial PANSS score was 57.28 in risperidone(R), 60.47 in olanzapine(O) and 58.45 in control(H) group. PANSS score after 180 days was 34.32 in R, 35.58 in O and 37.97 in H group. There was no statistical difference in pretrial scores for PANSS (p = 0.691), CGI1 (p = 0.733), CGI2 (p = 1.000), and CGI3 (p = 1.000) scores. There was statistical significance in PANSS and CGI1-4 score reduction after 180 days in all groups (p = 0.000). There was no statistical difference in PANSS score reduction between R and H (p = 0.114) and O and H group (p = 0.136). CGI1-4 scores reduction: CGI1, Rvs.H, p = 0.019 and Ovs.H, p = 0.032 with high statistical significance; CGI2, Rvs.H, p = 0.153 and Ovs.H, p = 0.179 with no statistical significance; CGI3, Rvs.H, p = 0.183 and Ovs.H, p = 0.161 with no statistical significance; CGI4, Rvs.H, p = 0.000 and Ovs.H, p = 0.000 with high statistical significance. Adverse effects were significantly lower in Risperidone (21.42%) and Olanzapine (21.81%) than in Haloperidol (57.5%) group.

Conclusion

Risperidone and Olanzapine have slightly better efficacy in treatment of DD comparing to haloperidol, with statisticaly significant lower adverse effects rate.

Type
P03-132
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 1301
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.